Bradley Kalinsky, MD
Nephrology · North Charleston, SCNPI 1386818698
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (40.1%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 32 manufacturers reported payments, led by Nipro Medical Corporation at 38.2% of the total. Reporting peaked in 2023 at $4,843 and has fallen 77.8% since, to $1,075 in 2025. Among nephrology clinicians in SC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 152 payments — averaging $75.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Nipro Medical Corporation$4K
- Mallinckrodt Enterprises LLC$4K
- Vifor Pharma, Inc.$505
- Amgen$415
- Otsuka America Pharmaceutical, Inc.$359
- Travere Therapeutics, Inc.$310
- plus $2K from 26 others
What the payments were for
- Consulting fees$4,60340%
- Speaking & faculty fees$3,40030%
- Food & beverage$3,41630%
- Education$520%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Nipro Medical Corporation | 1 | $4,378 |
| Mallinckrodt Enterprises LLC | 7 | $3,572 |
| Vifor Pharma, Inc. | 23 | $505 |
| Amgen(2 entities) | 18 | $415 |
| Otsuka America Pharmaceutical, Inc. | 15 | $359 |
| Travere Therapeutics, Inc. | 7 | $310 |
| Calliditas Therapeutics US Inc. | 5 | $199 |
| Novartis | 12 | $188 |
| Mallinckrodt Hospital Products Inc. | 4 | $174 |
| Novo Nordisk | 6 | $146 |
| Johnson & Johnson | 3 | $125 |
| Baxter Healthcare | 2 | $125 |
| AstraZeneca(2 entities) | 8 | $122 |
| Aurinia Pharma U.S., Inc. | 4 | $98 |
| Alnylam Pharmaceuticals Inc. | 5 | $90 |
| Ardelyx, Inc. | 3 | $81 |
| Bayer | 4 | $78 |
| OPKO Pharmaceuticals, LLC | 4 | $72 |
| Fresenius USA Marketing, Inc. | 4 | $70 |
| Boehringer Ingelheim | 3 | $64 |
| GSK | 3 | $54 |
| Cormedix Inc. | 1 | $36 |
| Apellis Pharmaceuticals, Inc. | 1 | $31 |
| Akebia Therapeutics Inc | 1 | $25 |
| Scpharmaceuticals Inc. | 1 | $24 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $22 |
| Bristol Myers Squibb | 1 | $21 |
| Kyowa Kirin, Inc. | 1 | $21 |
| Daiichi Sankyo Inc. | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Ultragenyx Pharmaceutical Inc. | 1 | $16 |
| Shire North American Group Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ACTHAR$3,626
- TARPEYO$123
- Renal - Chronic$111
- Veltassa$108
How this compares
$11,471 in reported general payments places this provider in the 90th percentile of 180 nephrology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 155 | $117,543 |
| FarxigaDapagliflozin Propanediol | 111 | $94,745 |
| VeltassaPatiromer Calcium Sorbitex | 50 | $50,826 |
| LokelmaSodium Zirconium Cyclosilicate | 18 | $15,634 |
| KerendiaFinerenone | 18 | $11,442 |
| DapagliflozinDapagliflozin Propanediol | 17 | $8,254 |
| EliquisApixaban | 12 | $7,574 |
| Sevelamer Carbonate | 22 | $4,682 |
| Calcium Acetate | 16 | $967 |
| Nifedipine ErNifedipine | 38 | $892 |
| Doxazosin Mesylate | 37 | $883 |
| Bumetanide | 18 | $856 |
| Amlodipine Besylate | 96 | $730 |
| Carvedilol | 34 | $635 |
| Losartan Potassium | 79 | $546 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $64 | $117,543155 claims |
| AstraZenecaFarxiga, Lokelma | $122 | $110,379129 claims |
| BayerKerendia | $78 | $11,44218 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 180 nephrology providers in South Carolina.
Other nephrology in North Charleston
- Benjamin WeathersbyNorth Charleston$14K
- Richard BrowderNorth Charleston$6K
- Norwood HamiltonNorth Charleston$5K
- Jessica ColemanBeaufort$930K
- Moustafa MoustafaOrangeburg$616K
- Harold SzerlipCharleston$229K
- Barry GorlitskyGreenville$195K
- Blake ShustermanGreenville$66K
- Martin WebbBeaufort$66K
- Mohammed AlzubaidiSumter$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.